Doxorubicin (Adriamycin) for Mesothelioma

Doxorubicin, marketed as Adriamycin, is an anthracycline chemotherapy antibiotic that has been used in the treatment of malignant mesothelioma since the 1980s. While it has largely been supplanted by the pemetrexed/cisplatin combination as standard first-line therapy, doxorubicin continues to play a role in specific clinical scenarios, including intracavitary chemotherapy, heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, and selected combination regimens.¹

Doxorubicin works through multiple mechanisms: it intercalates between DNA base pairs, inhibits topoisomerase II (an enzyme essential for DNA replication), and generates reactive oxygen species (free radicals) that damage cellular DNA and membranes. This multi-pronged attack makes it one of the most broadly effective chemotherapy drugs ever developed, with activity across more than 50 cancer types. However, its effectiveness in mesothelioma as a single systemic agent is modest, with response rates of 10–20% in clinical trials.²

The most significant limitation of doxorubicin is its cumulative cardiac toxicity. The drug can cause irreversible damage to the heart muscle (cardiomyopathy), which limits the total lifetime dose a patient can receive to approximately 450–550 mg/m². A liposomal formulation (Doxil/Caelyx) encapsulates the drug in tiny lipid spheres, which reduces cardiac toxicity and improves drug delivery to tumor tissue. Liposomal doxorubicin has been studied in mesothelioma clinical trials with response rates of 6–14%.³

In contemporary mesothelioma practice, doxorubicin's most important application is in intracavitary therapy — direct instillation into the pleural or peritoneal space after surgical debulking. In HIPEC protocols for peritoneal mesothelioma, doxorubicin is sometimes combined with cisplatin and heated to 41–43°C, allowing high concentrations of the drug to contact residual tumor cells directly while limiting systemic exposure and cardiac risk.⁴

Doxorubicin is used in several treatment contexts for mesothelioma, though it is no longer considered a standard first-line systemic agent:¹

Historical Systemic Regimens

Before the approval of pemetrexed in 2004, doxorubicin was one of the most commonly used chemotherapy agents for mesothelioma, often in combination regimens:²

• Doxorubicin single agent — 60–75 mg/m² every 21 days; response rate 10–20%
• Doxorubicin + cisplatin — Response rates of 20–28% in phase II trials
• CAP regimen (cyclophosphamide + doxorubicin + cisplatin) — Used historically with response rates of approximately 25%

Intracavitary and HIPEC Use

Doxorubicin's current role centers on direct intracavitary administration:⁴

• Intrapleural instillation — Direct delivery into the pleural space after pleurodesis or surgical drainage, achieving high local drug concentrations
• HIPEC for peritoneal mesothelioma — 15–90 mg doxorubicin added to heated cisplatin perfusion during cytoreductive surgery, circulated at 41–43°C for 60–90 minutes

Liposomal Doxorubicin (Doxil/Caelyx)

The liposomal formulation has been studied in mesothelioma clinical trials:³

• Dosing — 40–50 mg/m² every 28 days
• Response rate — 6–14% as single agent in mesothelioma
• Advantage — Reduced cardiac toxicity compared to conventional doxorubicin, allowing longer treatment duration
• Side effects — Hand-foot syndrome (palmar-plantar erythrodysesthesia) is the dose-limiting toxicity of the liposomal formulation

Doxorubicin provides modest activity in mesothelioma when used systemically, though its intracavitary applications may offer greater benefit:²

• Single-agent systemic response rate — 10–20%, lower than pemetrexed-based regimens
• Combination with cisplatin — Response rates of 20–28%, historically considered active but now superseded by pemetrexed/cisplatin
• HIPEC protocols — Intracavitary doxorubicin combined with cytoreductive surgery for peritoneal mesothelioma has shown median survival of 34–92 months in selected patients at experienced centers
• Disease control — Stable disease achieved in an additional 30–40% of patients beyond those with objective responses

Managing the side effects of doxorubicin requires careful monitoring, particularly of cardiac function:²

• Cardiac monitoring — Echocardiogram or MUGA scan before starting treatment and periodically during therapy to monitor left ventricular ejection fraction. Treatment is typically discontinued if ejection fraction drops below 40–45%
• Nausea and vomiting — Doxorubicin is moderately to highly emetogenic. Standard anti-emetic prophylaxis with a 5-HT3 antagonist and dexamethasone is recommended
• Hair loss (alopecia) — Complete hair loss occurs in most patients receiving doxorubicin. Hair typically regrows 2–3 months after treatment completion
• Myelosuppression — Neutropenia is common, with nadir occurring 10–14 days after each dose. Blood counts should be checked weekly, and treatment delayed if neutrophil count is below 1,500/mm³
• Mucositis — Mouth sores occur in 20–40% of patients. Good oral hygiene, gentle mouthwashes, and avoiding hot or spicy foods can reduce severity
• Red urine — Doxorubicin turns urine red-orange for 1–2 days after infusion. This is harmless and expected, not a sign of bleeding
• Vesicant risk — Like vinorelbine, doxorubicin causes severe tissue damage if it extravasates (leaks outside the vein). Infusion through a central line is preferred